Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug3126 | Pemziviptadil (PB1046) Wiki | 0.58 |
| drug3448 | Pulmonary Vascular Permeability Index Wiki | 0.58 |
| drug1599 | Extravascular Lung Water Index Wiki | 0.58 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D000075902 | Clinical Deterioration NIH | 0.41 |
| D011665 | Pulmonary Valve Insufficiency NIH | 0.19 |
| D006333 | Heart Failure NIH | 0.14 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| HP:0100598 | Pulmonary edema HPO | 1.00 |
| HP:0010444 | Pulmonary insufficiency HPO | 0.19 |
| HP:0001635 | Congestive heart failure HPO | 0.14 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| HP:0002090 | Pneumonia HPO | 0.03 |
Navigate: Correlations HPO
There are 3 clinical trials
This is a multicenter, randomized, double-blind, parallel group study to investigate the efficacy of pemziviptadil (PB1046) by improving the clinical outcomes in hospitalized COVID-19 patients at high risk for rapid clinical deterioration, acute respiratory distress syndrome (ARDS) and death. The study will enroll approximately 210 hospitalized COVID-19 patients who require urgent decision-making and treatment at approximately 20 centers in the United States.
Description: Composite of: Total hospital days, Total ICU days, Total days of ventilator use, Total days of ECMO, Total days of invasive hemodynamic monitoring, Total days of mechanical circulatory support, Total days of inotropic or vasopressor therapy
Measure: Reduction in hospital resource utilization defined as a composite of: total days: in hospital, in ICU, on ventilator, on ECMO, with invasive hemodynamic monitoring, with mechanical circulatory support, and with inotropic or vasopressor therapy Time: 28 daysCovid-19 also primarily affects endothelium that line up the alveoli. The resulting hypoxemia may differ from "typical" Acute Respiratory Distress Syndrome (ARDS) due to maldistribution of perfusion related to the ventilation. Thus, pathophysiology of Covid-19 ARDS is different, which requires different interventions than typical ARDS. The investigators will assess whether extravascular lung water index and permeability of the alveolar capillary differs from typical ARDS with transpulmonary thermodilution (TPTD) technique. Extravascular Lung Water Index (EVLWI) and Pulmonary Vascular Permeability Index (PVPI) will be compared.
Description: The amount of fluid accumulated in the lung measured by transpulmonary thermodilution (ml/kg)
Measure: Extravascular Lung Water Index Time: 1 dayDescription: Integrity of the alveolocapillary barrier measured by transpulmonary thermodilution
Measure: Pulmonary vascular permeability index Time: 1 dayThe clinical trial will evaluate the short term and extended impact on on respiration, pulmonary function and cardiovascular function in C2Rx treatment verse Standard of Care (SOC) in critically ill adults with COVID-19 infections .
Description: Change in patient Arterial Oxygen Partial Pressure (PaO2)/Fractional Inspired Oxygen (FiO2) Ratio
Measure: Pulmonary Oxygenation Function Time: Up to 72 hoursDescription: Change in patient oxygenation
Measure: Pulmonary Compliance of Respiratory System (CRS) Time: Up to 96 hoursDescription: Change in the total number of patients that survived
Measure: Survival Time: 30 days and 60 daysDescription: Change in Hospital Utilization of ventilators (days)
Measure: Hospital Costs 1 Time: Out to 60 daysDescription: Change in score based on the calculation of the following medications used: dopamine dose (µg/kg/min) + dobutamine dose (µg/kg/min) + 100 x adrenaline dose (µg/kg/min) + 100 x noradrenaline dose (µg/kg/min) + 10 x milrinone dose (µg/kg/min) + 10.000 x vasopressin dose (U/kg/min)
Measure: Cardiovascular Vasoactive-Inotropic Score (VIS) Time: Up to 96 hoursDescription: Change in Hospital Utilization of vasopressor medication (days without use)
Measure: Hospital Costs 2 Time: Out to 60 daysDescription: Change in Hospital Utilization of Intensive Care Unit (ICU) Hospital free days
Measure: Hospital Costs 3 Time: Out to 60 daysDescription: Change in Hospital Utilization of Renal Replacement Therapy (days on therapy)
Measure: Hospital Costs 4 Time: Out to 60 daysDescription: Change in Hospital Utilization (days hospitalized)
Measure: Hospital Costs 5 Time: Out to 60 daysDescription: Changes in inflammatory mediators detected by Immunoassay of Multianalyte Panel - MAP Laboratory Panel of 253 analytes.
Measure: Inflammatory mediators in blood Time: Out to 14 hoursDescription: Change in cytokine levels obtained from plasma and blood collected prior to and after filter. Analyte concentrations in ultrafiltrate and plasma, expressed in the same concentration units, will be aggregated as a ratio of ultrafiltrate concentration to plasma concentration to yield a unitless Sieving Coefficient (SC). SC is an index of membrane function.
Measure: Cytokine Sieving Effects Time: Out to 8 hoursDescription: Change in blood Ferritin (mg/mL)
Measure: Specific Blood Indicators 1 Time: Out to 14 hoursDescription: Change in blood Interleukin-6 (pg/mL)
Measure: Specific Blood Indicators 2 Time: Out to 14 hoursDescription: Change in blood C-reactive protein (CRP) (mg/L)
Measure: Specific Blood Indicators 3 Time: Out to 14 hoursDescription: Change in blood Lactate Dehydrogenase (LDH) (U/L)
Measure: Specific Blood Indicators 4 Time: Out to 14 hoursDescription: Change in blood D-dimer (mcg/L*FEU2)
Measure: Specific Blood Indicators 5 Time: Out to 14 hoursDescription: Change in blood White Blood Cell (WBC) count (%)
Measure: Specific Blood Indicators 6 Time: Out to 14 hoursDescription: Change in blood Neutrophil count (%)
Measure: Specific Blood Indicators 7 Time: Out to 14 hoursDescription: Change in blood lymphocyte count (%).
Measure: Specific Blood Indicators 8 Time: Out to 14 hoursDescription: Change in the duration of days of diagnosed HAI/ Sepsis infections
Measure: Hospital Acquired Infections (HAI) /Sepsis Time: 30 and 60 daysDescription: Duration without Respiratory Replacement Therapy (RRT), ventilator, and time to discharge
Measure: Composite Recovery Time: Up to 30 daysDescription: Survival without Respiratory Replacement Therapy (RRT), ventilator, or time to Long Term Care (LTC)
Measure: Composite Survival Time: 30 and 60 daysDescription: Survival with Respiratory Replacement Therapy (RRT), ventilator or in Long Term Care (LTC)
Measure: Composite Non-Recovery Time: Up to 60 daysAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on December 13, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports